Policy: Tectonic Shift
Pharmaceutical Executive
Pretoria, South Africa-Few people noticed that the ground had begun to crumble under Big Pharma when, after the failed World Trade Organization talks in Seattle, Washington, the Clinton administration indicated that it would take note of the effects of its trade policies on healthcare in developing countries. Multinational companies had hitherto been able to take the support of governments for granted when it came to policing intellectual property, but Clinton's move indicated a major shift in policy. Few noticed, because the rhetoric wasn't immediately matched by reality. In fact, the US government continued to pressure countries whose intellectual property protection seemed too weak. Then the new Bush administration, thought to be an unwavering ally of the pharmaceutical industry, indicated it would continue the Clinton policy.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
